Eduardo Cronemberger

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC

Shun Lu, Terufumi Kato, Xiaorong Dong et al. · New England Journal of Medicine · 2024 · 295 citations

Medicine, Oncology, Pharmacology +15

The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

Daniela Dornelles Rosa, José Bines, Gustavo Werutsky et al. · Breast Cancer Research and Treatment · 2020 · 70 citations

Medicine, Health Sciences, Oncology +13

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Sara A. Hurvitz, Cristina Saura, Mafalda Oliveira et al. · The Oncologist · 2021 · 62 citations · Full text

Medicine, Oncology, Pharmacology +17

Advanced Stage at Diagnosis and Worse Clinicopathologic Features in Young Women with Breast Cancer in Brazil: A Subanalysis of the AMAZONA III Study (GBECAM 0115)

Maria Alice Franzoi, Daniela Dornelles Rosa, Facundo Zaffaroni et al. · Journal of Global Oncology · 2019 · 59 citations · Full text

Medicine, Oncology, Pathology +12